Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05268081
Other study ID # 1-30-72-353-21
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 1, 2022
Est. completion date June 30, 2024

Study information

Verified date May 2023
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To support the primary care sector in delivering high-quality Type 2-diabetes (T2D), literature reviews emphasize the need for implementing models of collaboration that in a simple and effective way facilitate clinical dialogue between general practitioners (GPs) and endocrinologists. The overall aim of the project is to study if an intervention consisting of structured cross-sectoral and virtual conferences between GPs and endocrinologists about T2D improves diabetes care and increases diabetes competencies and management in general practice. This aim will be studied in a pragmatic randomized controlled trial design. This potential is yet to be fully tapped because of methodological limitations. Studies have also not yet systematically evaluated virtual conferences in the context of chronic care using a high-quality research design.


Description:

The overall aim is to study if cross-sectoral and virtual specialist conferences improves diabetes care and increases diabetes competencies and management in general practice. The expectation is that the intervention will: at the patient level: - improve adherence to international recommendations on diabetes medication for patients with Type 2-diabetes (T2D) - improve the risk profile of patients with T2D with a reduction in glycated haemoglobin, blood pressure and cholesterol at the general practice level: - improve the self-reported competence and confidence in management of patients with T2D among general practitioners and practice staff The intervention consists of four virtual and thematic conferences: (1) T2D and cardiovascular disease and heart failure, (2) T2D and lipids, (3) T2D and kidney disease and blood pressure, and (4) T2D and a free topic selected by the general practitioner (GP). Before having the first virtual conference, an introductory webinar is held to learn GPs about how to use the electronic "Diabetes Overview" to identify and manage patients with T2D. Each general practice is assigned to an endocrinologist who they meet at all four conferences. The intervention was developed using the Medical Research Framework for developing complex interventions. All general practices located in the Municipality of Aarhus, Denmark are invited (n = 100). Block randomization is performed at the general practice level, and general practices will be randomized in a 1:1 ratio to either the intervention or the control group.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 25
Est. completion date June 30, 2024
Est. primary completion date August 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - General practices are eligible for inclusion if licensed and located in the municipality of Aarhus. - GPs must consent to participate in the intervention and collect the data needed to measure patient and general practice outcomes. - GPs must agree to bring patient cases to the virtual conferences who are =18 years, diagnosed with T2D and who they would like to discuss with the endocrinologist. Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Virtual specialist conferences
The intervention consists of four virtual conferences (45 min each in month 2, 5, 8 and 11) and an introductory webinar (90 min in month 1) to learn GPs about how to use the electronic "Diabetes Overview" to identify and manage patients with T2D. Each general practice is assigned to one specific endocrinologist they meet with throughout. The four virtual conferences are thematic: T2D and cardiovascular disease and heart failure, T2D and lipids, T2D and kidney disease and blood pressure, and T2D and a free topic selected by the GP. At each conference, the GP must bring 2-3 patient cases related to the theme and 1-2 patients of their own choice. The GP chairs the meeting. Each conference follows the same format: Check in (5 min); Short presentation by the endocrinologist (10 min); Presentation by GP and joint dialogue about theme-related patients (20 min); Presentation by GP and joint dialogue about theme-unrelated patients (optional, 5 min); (5) Wrapping-up (5 min).

Locations

Country Name City State
Denmark Steno Diabetes Center Aarhus Aarhus N Danmark

Sponsors (3)

Lead Sponsor Collaborator
University of Aarhus Aarhus University Hospital, Region MidtJylland Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ischemic heart disease and/or stroke treated with GLP1-RA and SGLT2 inhibitor Percentage of patients with type 2-diabetes and ischemic heart disease and/or stroke being treated with glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium glucose cotransporter 2 (SGLT2) inhibitor Month 12
Primary Micro/macro-albuminuria treated with ACE-inhibitor or AT2 Percentage of patients with type 2-diabetes and micro/macro-albuminuria being treated with Angiotensin-converting-enzyme-inhibitor (ACE) or angiotensin-2-receptorantagonist (AT2) Month 12
Primary LDL>2.5 mmol/L treated with Statins Percentage of patients with type 2-diabetes and LDL>2.5 mmol/L being treated with Statins Month 12
Primary Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes in general Self-reported degree to which the general practitioner is confident in: managing diabetes; managing patients with diabetes; managing patients with complex diabetes; managing patients with diabetes who are non-compliant.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12
Primary Questionnaire for the assessment of general practitioners' skills in managing type-2 diabetes in general Self-reported degree to which the general practitioner is confident in: assessing when it is appropriate to initiate insulin treatment; selecting the appropriate medicine, when patients with diabetes need three-agent antidiabetics; selecting the appropriate medicine, when patients with have co-morbidity; achieving a lower level of Hb1Ac in patients with diabetes; high treatment quality for patients with diabetes; setting treatment targets for patients with diabetes; referring the right patients with diabetes to the department of endocrinology.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12
Primary Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and cardiovascular disease or heart failure Self-reported degree to which the general practitioner is confident in: managing cardiovascular disease in patients with diabetes; assessing risk of cardiovascular disease in patients with diabetes; selecting the most appropriate medication for patients with diabetes and cardiovascular disease; achieving high treatment quality for patients with diabetes and cardiovascular disease; managing heart failure in patients with diabetes; assessing risk of heart failure in patients with diabetes; selecting the most appropriate medication for patients with diabetes and heart failure; achieving high treatment quality for patients with diabetes and heart failure.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12
Primary Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and blood pressure Self-reported degree to which the general practitioner is confident in: managing high blood pressure in patients with diabetes; selecting the most appropriate medication for patients with diabetes and high blood pressure; achieving high treatment quality for patients with diabetes and high blood pressure.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12
Primary Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and kidney disease Self-reported degree to which the general practitioner is confident in: managing kidney disease in patients with diabetes; managing Estimated Glomerular Filtration Rate (eGFR) in patients with diabetes; managing albuminuria in patients with diabetes; selecting the most appropriate medication for patients with diabetes if they have kidney disease in the form of lowered eGFR; selecting the most appropriate medication for patients with diabetes if they have kidney disease in the form of albuminuria; achieving high treatment quality for patients with diabetes and kidney disease.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12
Primary Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and cholesterol Self-reported degree to which the general practitioner is confident in: managing high cholesterol in patients with diabetes; selecting the most appropriate cholesterol lowering medication for patients with diabetes; achieving a lower level of cholesterol among patients with diabetes and high cholesterol.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12
Secondary Ischemic heart disease and/or stroke treated with GLP1-RA and SGLT2 inhibitor Percentage of patients with type 2-diabetes and ischemic heart disease and/or stroke being treated with glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium glucose cotransporter 2 (SGLT2) inhibitor Month 24
Secondary Micro/macro-albuminuria treated with ACE-inhibitor or AT2 Percentage of patients with type 2-diabetes and micro/macro-albuminuria being treated with Angiotensin-converting-enzyme-inhibitor (ACE) or angiotensin-2-receptorantagonist (AT2) Month 24
Secondary LDL>2.5 mmol/L treated with Statins Percentage of patients with type 2-diabetes and LDL>2.5 mmol/L being treated with Statins Month 24
Secondary Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes in general at 24 month Self-reported degree to which the general practitioner is confident in: managing diabetes; managing patients with diabetes; managing patients with complex diabetes; managing patients with diabetes who are non-compliant.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 24
Secondary Questionnaire for the assessment of general practitioners' skills in managing type-2 diabetes in general at 24 month Self-reported degree to which the general practitioner is confident in: assessing when it is appropriate to initiate insulin treatment; selecting the appropriate medicine, when patients with diabetes need three-agent antidiabetics; selecting the appropriate medicine, when patients with have co-morbidity; achieving a lower level of Hb1Ac in patients with diabetes; high treatment quality for patients with diabetes; setting treatment targets for patients with diabetes; referring the right patients with diabetes to the department of endocrinology.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 24
Secondary Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and cardiovascular disease or heart failure at 24 month Self-reported degree to which the general practitioner is confident in: managing cardiovascular disease in patients with diabetes; assessing risk of cardiovascular disease in patients with diabetes; selecting the most appropriate medication for patients with diabetes and cardiovascular disease; achieving high treatment quality for patients with diabetes and cardiovascular disease; managing heart failure in patients with diabetes; assessing risk of heart failure in patients with diabetes; selecting the most appropriate medication for patients with diabetes and heart failure; achieving high treatment quality for patients with diabetes and heart failure.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 24
Secondary Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and blood pressure at 24 month Self-reported degree to which the general practitioner is confident in: managing high blood pressure in patients with diabetes; selecting the most appropriate medication for patients with diabetes and high blood pressure; achieving high treatment quality for patients with diabetes and high blood pressure.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 24
Secondary Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and kidney disease at 24 month Self-reported degree to which the general practitioner is confident in: managing kidney disease in patients with diabetes; managing Estimated Glomerular Filtration Rate (eGFR) in patients with diabetes; managing albuminuria in patients with diabetes; selecting the most appropriate medication for patients with diabetes if they have kidney disease in the form of lowered eGFR; selecting the most appropriate medication for patients with diabetes if they have kidney disease in the form of albuminuria; achieving high treatment quality for patients with diabetes and kidney disease.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 24
Secondary Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and cholesterol at 24 month Self-reported degree to which the general practitioner is confident in: managing high cholesterol in patients with diabetes; selecting the most appropriate cholesterol lowering medication for patients with diabetes; achieving a lower level of cholesterol among patients with diabetes and high cholesterol.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 24
Secondary Patients with T2D and HbA1c <58 mmol/L at 12 and 24 months Percentage of patients with type 2-diabetes and HbA1c <58 mmol/L Month 12 and Month 24
Secondary Patients with T2D and HbA1c <53 mmol/L at 12 and 24 months Percentage of patients with type 2-diabetes and HbA1c <53 mmol/L Month 12 and Month 24
Secondary Patients with T2D and blood pressure <140 mmHg at 12 and 24 months Percentage of patients with type 2-diabetes and blood pressure <140 mmHg Month 12 and Month 24
Secondary Patients with T2D and blood pressure <130 mmHg at 12 and 24 months Percentage of patients with type 2-diabetes and blood pressure <130 mmHg Month 12 and Month 24
Secondary Patients with T2D and LDL >2.5 mmol/L at 12 and 24 months Percentage of patients with type 2-diabetes and low-density lipoprotein >2.5 mmol/L Month 12 and Month 24
Secondary Patients with T2D and microalbuminuria and LDL >1.8 mmol/L at 12 and 24 months Percentage of patients with type 2-diabetes and microalbuminuria and LDL >1.8 mmol/L Month 12 and Month 24
Secondary Questionnaire for the assessment of general practitioners' rating of relational coordination in the general practice at 12 and 24 months Self-reported assessment by the general practitioner about their collaboration with the general practice using the relational coordination survey that measures the degree of: Frequent Communication; Timely Communication; Accurate Communication; Problem Solving Communication; Shared Goals; Shared Knowledge; Mutual Respect.
Range 1-5, higher score indicates relational coordination.
Month 12 and Month 24
Secondary Questionnaire for the assessment of general practitioners' rating of relational coordination with the hospital at 12 and 24 months Self-reported assessment by the general practitioner about their collaboration with the hospital using the relational coordination survey that measures the degree of: Frequent Communication; Timely Communication; Accurate Communication; Problem Solving Communication; Shared Goals; Shared Knowledge; Mutual Respect.
Range 1-5, higher score indicates relational coordination.
Month 12 and Month 24
Secondary Questionnaire for the assessment of general practitioners' rating of using virtual conferences at 12 and 24 months Self-reported assessment by the general practitioner about using virtual conferences measured along the four dimensions of the Technology Acceptance Model: perceived usefulness of virtual conferences; perceived ease-of-use of virtual conferences; attitude to using virtual conferences; behavioural intention as regards using virtual conferences.
Range 1-5 from "completely disagree" to "completely agree", higher score indicates higher user ratings.
Month 12 and Month 24
Secondary Questionnaire for the assessment of practice staffs' rating of relational coordination in the general practice at 12 and 24 months Self-reported assessment by the practice staff about their collaboration with the general practice using the relational coordination survey that measures the degree of: Frequent Communication; Timely Communication; Accurate Communication; Problem Solving Communication; Shared Goals; Shared Knowledge; Mutual Respect.
Range 1-5, higher score indicates higher relational coordination.
Month 12 and Month 24
Secondary Questionnaire for the assessment of practice staffs' rating of relational coordination with the hospital at 12 and 24 months Self-reported assessment by the practice staff about their collaboration with the hospital using the relational coordination survey that measures the degree of: Frequent Communication; Timely Communication; Accurate Communication; Problem Solving Communication; Shared Goals; Shared Knowledge; Mutual Respect.
Range 1-5, higher score indicates higher relational coordination.
Month 12 and Month 24
Secondary Questionnaire for the assessment of practice staffs' rating of using virtual conferences at 12 and 24 months Self-reported assessment by the practice staff about using virtual conferences measured along four dimensions of the Technology Acceptance Model: perceived usefulness of virtual conferences; perceived ease-of-use of virtual conferences; attitude to using virtual conferences; behavioural intention as regards using virtual conferences.
Range 1-5 from "completely disagree" to "completely agree", higher score indicates higher user ratings.
Month 12 and Month 24
Secondary Questionnaire for the assessment of practice staffs' confidence in managing type-2 diabetes in general at 12 and 24 month Self-reported degree to which the practice staff is confident in: managing diabetes; managing patients with diabetes; managing patients with complex diabetes; managing patients with diabetes who are non-compliant; achieving high treatment quality for patients with diabetes.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12 and Month 24
Secondary Questionnaire for the assessment of practice staffs' confidence in managing type-2 diabetes and cardiovascular disease or heart failure at 12 and 24 month Self-reported degree to which the practice staff is confident in: managing cardiovascular disease in patients with diabetes; assessing risk of cardiovascular disease in patients with diabetes; achieving high treatment quality for patients with diabetes and cardiovascular disease; managing heart failure in patients with diabetes; assessing risk of heart failure in patients with diabetes; achieving high treatment quality for patients with diabetes and heart failure.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12 and Month 24
Secondary Questionnaire for the assessment of practice staffs' confidence in managing type-2 diabetes and blood pressure at 12 and 24 months Self-reported degree to which the practice staff is confident in: managing high blood pressure in patients with diabetes; achieving high treatment quality for patients with diabetes and high blood pressure.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12 and Month 24
Secondary Questionnaire for the assessment of practice staffs' confidence in managing type-2 diabetes and kidney disease at 12 and 24 months Self-reported degree to which the practice staff is confident in: managing kidney disease in patients with diabetes; achieving high treatment quality for patients with diabetes and kidney disease.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12 and Month 24
Secondary Questionnaire for the assessment of practice staffs' confidence in managing type-2 diabetes and cholesterol at 12 and 24 month Self-reported degree to which the practice staff is confident in managing high cholesterol in patients with diabetes.
Range 1-5 from "not at all" to "a very high degree", higher score indicates higher confidence.
Month 12 and Month 24
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2

External Links